A population-based study of the impact of dialysis on mortality in multiple myeloma. Evison F et al. Br J Haematol. 2016 Oct 21. doi: 10.1111/bjh.14394. [Epub ahead of print]. Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study. Yin QS et al. Med Sci Monit. 2016 Oct 20;22:3835-3842. Effect of Systemic Therapies…
DetailsManagement of gynaecologic plasmacytoma: A review article. Feldman AM et al. J Obstet Gynaecol. 2016 Oct 19:1-6. [Epub ahead of print]. Current treatments for renal failure due to multiple myeloma. Gavriatopoulou M et al. Expert Opin Pharmacother. 2016 Nov;17(16):2165-2177. Epub 2016 Sep 27. Comparative Confocal and Histopathological Study of Corneal Changes in Multiple Myeloma. Micali A et al. Cornea. 2016 Oct 5. [Epub ahead of print].…
DetailsOutcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Mateos MV et al. Ann Hematol. 2016 Oct 14. [Epub ahead of print]. Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for…
DetailsUtility of flow cytometry studies in the management of patients with multiple myeloma. Paiva B et al. Curr Opin Oncol. 2016 Sep 12. [Epub ahead of print]. Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma. Gupta R et al. Leuk Lymphoma. 2016 Sep 23:1-4. [Epub ahead of print]. Role of MRD status in relation to clinical outcomes in…
DetailsImmunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Gertz MA. Am J Hematol. 2016 Sep;91(9):947-56. doi: 10.1002/ajh.24433. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. Jelinek T et al. Hematol Oncol. 2016 Sep 20. doi: 10.1002/hon.2351. [Epub ahead of print]. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Falk RH et…
DetailsRicolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Yee AJ et al. Lancet Oncol. 2016 Sep 16. pii: S1470-2045(16)30375-8. doi: 10.1016/S1470-2045(16)30375-8. [Epub ahead of print]. A selective histone deacetylase inhibitor for myeloma. Pratt G et al. Lancet Oncol. 2016 Sep 16. pii: S1470-2045(16)30407-7. doi: 10.1016/S1470-2045(16)30407-7. [Epub ahead of print]. Vemurafenib in combination with cobimetinib in…
DetailsOutcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Bock F et al. Biol Blood Marrow Transplant. 2016 Sep 13. pii: S1083-8791(16)30329-9. doi: 10.1016/j.bbmt.2016.09.003. [Epub ahead of print]. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Gaballa S et al. Am J Hematol. 2016 Oct;91(10):E442-7. doi: 10.1002/ajh.24487. Epub 2016 Sep 3.…
DetailsAdvances in understanding prognosis in myeloma. Smith D et al. Br J Haematol. 2016 Sep 8. doi: 10.1111/bjh.14304. [Epub ahead of print]. Stem Cell Transplantation In Multiple Myeloma. Offidani M et al. Curr Cancer Drug Targets. 2016 Sep 19. [Epub ahead of print]. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modernmultiple myeloma therapy. Voorhees PM et…
DetailsTherapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis. Kobayashi T et al. Ann Hematol. 2016 Sep 6. [Epub ahead of print]. Mid-term outcomes after radiofrequency-targeted vertebral augmentation in the treatment of myeloma associated vertebral fractures. Ali T et al. Technol Health Care. 2016 Sep 14;24(5):745-51. doi: 10.3233/THC-161222. Pharmacokinetics of Cefepime in Patients with Cancer and Febrile…
Details